2 assets in Erythrocyte Disorder

Therapeutic assets addressing Erythrocyte Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Erythrocyte Disorder	University of Calgary	P2	CCC (53)
Sirolimus Erythrocyte Disorder	University of Calgary	P2	CCC (53)